https://orcid.org/0000-0002-7976-8287
References
- Cunningham FG. Physiology of pregnancy. In: Cunningham FG, editor. Williams obstetrics. 21st ed. New York (NY): McGraw-Hill; 2001.
- Meis PJ, Connors N. Progesterone treatment to preventpre-term birth. Clin Obstet Gynecol. 2004;47:784–795.
- Palagiano A, Bulletti C, Pace MC, et al. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci. 2004;1034(1):200–210.
- Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. BMJ. 2004; 329(7458):152–155.
- Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2008;2:CD003511.
- Wahabi HA, Abed Althagafi NF, Elawad M, et al. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011;3:CD005943.
- Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2013;10:CD003511.
- Wahabi HA, Fayed AA, Esmaeil SA, et al. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2018;8:CD005943.
- Giorlandino C, Cignini P, Padula F, et al. Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study. Am J Obstet Gynecol. 2015;212(3):335.e1–335.e7.
- Keçecioğlu M, Tokmak A, Kekmakoğlu TS, et al. Does progesterone therapy increase nuchal translucency in women with threatened miscarriage? Ginekol Pol. 2016;87(5):390–394.
- Miller NR, Dolinsky BM, Napolitano PG. Micronized progesterone reduces vasoconstriction in the placenta. J Matern-Fetal Neonatal Med. 2015;28(13):1581–1584.
- Spencer K, Ong CY, Liao AW, et al. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn. 2000c;20(6):491–494.
- Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn. 2003a;23(10):851–855.
- Spencer K, Ong CY, Liao AW, et al. The influence of parity and gravidity on first trimester markers of chromosomalabnormality. Prenat Diagn. 2000f;20(10):792–794.
- Spencer K, Bindra R, Cacho AM, et al. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn. 2004;24(3):169–171.
- Liao AW, Heath V, Kametas N, et al. First trimester screening for trisomy 21 in singleton pregnanciesachieved by assisted reproduction. Hum Reprod. 2001;16(7):1501–1504.
- Kagan KO, Wright D, Spencer K, et al. First trimester screening for trisomy 21 by free beta-humanchorionic gonadotropin and pregnancy associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol. 2008;31:493–502.
- Spencer K, Spencer CE, Stamatopoulou A. Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening. Prenat Diagn. 2010;30:547–550.
- Cuckle H, Van Oudgaarden ED, Mason G, et al. Taking account of vaginal bleeding in screening for Down syndrome. Br J Obstet Gynaecol. 1994;101(11):948–953.
- Heinig J, Steinhard J, Schmitz R. Does vaginal bleeding influence first-trimester markers for Down syndrome? Prenat Diagn. 2007;27:312–316.
- De Biasio P, Canini S, Crovo A, et al. Early vaginal bleeding and first-trimester markers for Down syndrome. Prenat Diagn. 2003;23(6):470–473.
- Namlı Kalem M, Kalem Z, Bakem Kal B, et al. The effect of progesterone use in the first trimester on fetal nuchal translucency. J Turk German Gynecol Assoc. 2018;19(1):29–33. 1
- Omar HA, Ramirez R, Gibson M. Properties of a progesterone-induced relaxation in human placental arteries and veins. J Clin Endocrinol Metab. 1995;80(2):370–373.